| Schedule of investments in and advances to affiliates |
The following table presents the wholly-owned subsidiaries of the Company as well as the entities in which the Company held a controlling financial interest as of December 31, 2025 and 2024: | | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, | | | | | 2025 | | 2024 | Entity name | | Jurisdiction of Incorporation/Formation | | Ownership %(1) | Curaleaf International Holdings Limited | | Guernsey | | 100% | | 68.5% | Curaleaf, Inc.* | | DE | | — | | — | Northern Green Canada Inc. | | Canada | | 100% | | 100% | Bloom Fungibles, LLC | | AZ | | 100% | | 100% | Focused Employer, Inc. | | DE | | 100% | | 100% | | | | | | | | (1) Based on % of voting interests held by the Company. | * Consolidated by the Company as a variable interest entity. See Note 3 — Significant accounting policies and Note 29 —Variable interest entities for further details. |
The following table presents the wholly-owned subsidiaries of Curaleaf International Holings Limited ("Curaleaf International") as well as the entities in which Curaleaf International held a controlling financial interest as of December 31, 2025 and 2024: | | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, | | | | | 2025 | | 2024 | Entity name | | Jurisdiction of Incorporation/Formation | | Ownership %(1) | Curaleaf International Limited | | UK | | 100% | | 100% | Four20 Pharma GmbH(2) | | Germany | | 55% | | 55% | | | | | | | | (1) Based on % of voting interests held by the Company. | (2) As of December 31, 2025 and 2024, the remaining 45% noncontrolling interest was held by the sellers of Four20 Pharma GmbH, which the Company acquired in September 2022. The remaining equity interest was acquired by the Company on April 30, 2026. See 'Non-controlling interests' herein and Note 18 — Redeemable non-controlling interest for further details. |
The following table presents the wholly-owned subsidiaries of Curaleaf, Inc. as well as the entities in which Curaleaf, Inc., directly or indirectly, held a controlling financial interest as of December 31, 2025 and 2024: | | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, | | | | | 2025 | | 2024 | Entity name | | Jurisdiction of Incorporation/Formation | | Ownership %(1) | CLF AZ, Inc. | | DE | | 100% | | 100% | CLF NY, Inc. | | DE | | 100% | | 100% | Curaleaf CA, Inc. | | DE | | 100% | | 100% | Curaleaf KY, Inc. | | DE | | 100% | | 100% | Curaleaf Massachusetts, Inc. | | MA | | 100% | | 100% | Curaleaf MD, LLC | | MD | | 100% | | 100% | Curaleaf OGT, Inc. | | DE | | 100% | | 100% | Curaleaf PA, LLC | | DE | | 100% | | 100% | Focused Investment Partners, LLC | | DE | | 100% | | 100% | CLF Maine, Inc. | | DE | | 100% | | 100% | PalliaTech CT, Inc. | | DE | | 100% | | 100% | PalliaTech Florida, Inc. | | DE | | 100% | | 100% | PT Nevada, Inc. | | DE | | 100% | | 100% | CLF Sapphire Holdings, Inc. | | DE | | 100% | | 100% | Curaleaf NJ II, Inc. | | DE | | 100% | | 100% | GR Companies, Inc. | | DE | | 100% | | 100% | CLF MD Employer, LLC | | MD | | 100% | | 100% | Curaleaf Columbia, LLC (formerly HMS Sales, LLC) | | MD | | 100% | | 100% | MI Health, LLC | | MD | | 100% | | 100% | Curaleaf Compassionate Care VA, LLC | | VA | | 100% | | 100% | Curaleaf UT, LLC | | DE | | 100% | | 100% | Curaleaf Processing, Inc | | DE | | 100% | | 100% | Virginia's Kitchen, LLC | | CO | | 100% | | 100% | Cura CO LLC | | CO | | 100% | | 100% | Curaleaf DH, Inc. | | DE | | 100% | | 100% | Curaleaf Stamford, Inc. | | CT | | 100% | | 100% | CLF Holdings Alabama, Inc. | | DE | | 100% | | 100% | IL Business Holding Corporation* | | IL | | — | | — | Broad Horizon Holdings, LLC* | | MA | | — | | — | CLF Oregon, LLC (formerly PalliaTech OR, LLC)(2) | | DE | | — | | 100% | Curaleaf Hemp, Inc.(2) | | DE | | — | | 100% | | | | | | | | (1) Based on % of voting interests held by Curaleaf, Inc. with the exception of the entities which Curaleaf, Inc. consolidates as variable interest entities. | (2) Entity dissolved in 2025. | * Consolidated by Curaleaf, Inc. as a variable interest entity. See Note 3 — Significant accounting policies and Note 29 — Variable interest entities for further details. |
|